NCT03061188: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma |
|
|
| Completed | 1 | 15 | US | Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888 | Northwestern University, Bristol-Myers Squibb, AbbVie, National Cancer Institute (NCI) | Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm | 03/18 | 08/20 | | |
